OGN
$6.39
Organon & Co.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internatio...
Recent News
A Look At Organon (OGN) Valuation After Recent Share Price Weakness
Organon (OGN) continues to attract attention after a challenging stretch, with the share price showing negative returns over the past year and past 3 months, prompting investors to reassess what the current valuation implies. See our latest analysis for Organon. The recent share price slide, including a 14.21% 30 day share price return and a 59.02% 1 year total shareholder return, points to fading momentum as investors reassess Organon’s risks and potential in light of its current US$6.34...
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 of Wall Street’s Favorite Stocks We Approach with Caution
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
3 Small-Cap Stocks We Approach with Caution
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.